News Sanofi abandons phase 3 trial of neurology drug riliprubart Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.
News Moderna jab on trial for cancer-causing syndrome Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.
News ADA: AZ reveals oral GLP-1 data in obesity, diabetes AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.
News ADA: Lilly's weight-loss reveal, and wannabes display wares Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.
News ADA: Safety data offset efficacy for survodutide New data with Zealand/Boehringer's survodutide reinforce its metabolic benefits, but a high discontinuation rate has raised concerns.
News First human trial backs AI-designed 'universal' vaccine An AI-powered universal vaccine tech developed by UK biotech DIOSynVax has shown preliminary efficacy in a world-first human trial.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.